Clinical trials: Prerequisite of evidence-based oncology. Reality, perspectives and a new tool recruited - The internet;Klinische studien: Fundament einer evidenz-basierten onkologie - Bestandsaufnahme und zukunft im zeitalter des internet

Onkologie

Volumn 24, Issue SUPPL. 1, 2001, Pages 24-34

  Mross, K ^a   Marz W ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Clinical research; Evidence based medicine; Internet

Indexed keywords

ANTINEOPLASTIC AGENT; NEW DRUG;

CANCER RESEARCH; CANCER SURVIVAL; CLINICAL RESEARCH; DNA MICROARRAY; DRUG DESIGN; EVIDENCE BASED MEDICINE; INTERNET; REVIEW; TELECOMMUNICATION;

CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; FORECASTING; GERMANY; HUMANS; INTERNET; MEDICAL ONCOLOGY; MULTICENTER STUDIES; RESEARCH; TREATMENT OUTCOME;

EID: 0035079280     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055162     Document Type: Review

References (36)

1. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey
2. Unconventional medicine in the United States - Prevalence, costs, and patterns of use
3. Let's stop giving alternative medicine a free ride
4. Alternative medicine - The risks of untested and unregulated remedies
5. The war on cancer: A review
6. A revolution in drug discovery. Combinatorial chemistry still needs logic to drive science forward
7. Molecular genomics and variability of drug metabolism
8. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias, including chronic myclogenous leukemia in blast crisis
9. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
10. Leukemia drug heralds molecularly targeted era
11. A gene expression database for the molecular pharmacology of cancer
12. p53-dependent cell death/apoptosis is required for a productive adenovirus infection
13. Has the smart bomb been defused?
14. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluoruracil in patients with recurrent head and neck cancer
15. There are no bad anticancer agents, only bad clinical trial designs
16. Impact of participation in randomized clinical trials on survival of women with early-stage breast cancer - An analysis of 7985 patients
17. Prognostic factors for survival in patients treated in phase I clinical trials
18. Patients in phase I trials of anticancer agents in Japan: Motivation comprehension and expectations
19. Patients' attitudes to participation in clinical trials
20. A quantitative survey of public attitudes towards cancer clinical trials
21. Klinische studien: Hilfe aus dem internet
22. Improved disease-free (dfs) and overall survival (os) from the addition of sequential paclitaxel (t) but not from the escalation of doxorubicin (a) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (bc)
23. Publication bias in clinical research
24. Underreporting research is scientific misconduct
25. Randomised, controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer
26. Surveys identify barriers to participation in clinical trials
27. Restructuring the NCI clinical trials system
28. Shopping around the internet today and tomorrow: Towards the millenium of cyber-medicine
29. Standard, Richtlinic oder Leitlinic
30. START: A European state-of-the-art on-line instrument for clinical oncologists
31. Better access to information about clinical trials
32. How useful is the web for clinical trial accrual? Three years experience with ACT!
33. Anspruch des Patienten auf Teihabe am medizinischen Fortschritt
34. Anspruch auf «gleiche» Behandlung angesichts des medizinischen Fortschritts?